Pietro Invernizzi
- Hepatology top 0.05%
- Liver Diseases and Immunity 208
- Liver Disease and Transplantation 24
- Epidemiology top 0.1%
- Liver Disease Diagnosis and Treatment 156
- Gastroenterology top 0.5%
- Surgery top 0.2%
- Pediatric Hepatobiliary Diseases and Treatments 73
- Cholangiocarcinoma and Gallbladder Cancer Studies 31
- Rheumatology top 0.5%
- Systemic Lupus Erythematosus Research 35
-
- Gallbladder and Bile Duct Disorders 26
-
- Drug Transport and Resistance Mechanisms 22
Pietro Invernizzi
334 papers receiving 14.4k citations
Hit Papers
Peers
Comparison fields: 5 of 144
- Hepatology 7.6k
- Epidemiology 6.9k
- Gastroenterology 634
- Surgery 5.0k
- Rheumatology 1.7k
Countries citing papers authored by Pietro Invernizzi
This map shows the geographic impact of Pietro Invernizzi's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Pietro Invernizzi with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Pietro Invernizzi more than expected).
Fields of papers citing papers by Pietro Invernizzi
This network shows the impact of papers produced by Pietro Invernizzi. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Pietro Invernizzi. The network helps show where Pietro Invernizzi may publish in the future.
Co-authorship network
The 25 scholars most cited alongside Pietro Invernizzi, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
| # | Work | ||
|---|---|---|---|
| 1 | 2024 | 3 | |
| 2 | 2024 | 10 | |
| 3 | 2024 | 1 | |
| 4 | 2024 | 1 | |
| 5 | 2023 | 37 | |
| 6 | 2023 | 25 | |
| 7 | 2023 | 22 | |
| 8 | 2023 | 1 | |
| 9 | 2023 | 24 | |
| 10 | 2022 | 16 | |
| 11 | 2020 | 18 | |
| 12 | 2018 | 8 | |
| 13 | 2017 | 33 | |
| 14 | 2016 | 70 | |
| 15 | 2013 | 47 | |
| 16 | 2009 | 1 | |
| 17 | 2008 | 93 | |
| 18 | Antidiabetic thiazolidinediones induce ductal differentiation but not apoptosis in pancreatic cancer cells | 2005 | 1 |
| 19 | 2005 | 144 | |
| 20 | 2002 | 48 |
About Pietro Invernizzi
Pietro Invernizzi is a scholar working on Hepatology, Epidemiology and Gastroenterology, having authored 344 papers that have together received 14.6k indexed citations. Recurring topics across this work include Liver Diseases and Immunity (208 papers), Liver Disease Diagnosis and Treatment (156 papers), Pediatric Hepatobiliary Diseases and Treatments (73 papers), Systemic Lupus Erythematosus Research (35 papers), Cholangiocarcinoma and Gallbladder Cancer Studies (31 papers), Gallbladder and Bile Duct Disorders (26 papers), Liver Disease and Transplantation (24 papers) and Drug Transport and Resistance Mechanisms (22 papers). The work is most often cited by research in Hepatology (7.6k citations), Epidemiology (6.9k citations) and Gastroenterology (634 citations). Pietro Invernizzi has collaborated with scholars based in Italy, United States and United Kingdom. Frequent co-authors include Mauro Podda, Carlo Selmi, Ana Lleò, M. Eric Gershwin, M. Eric Gershwin, Pier Maria Battezzati, Marco Marzioni, Gideon M. Hirschfield, David Jones and Massimo Zuin. Their work appears in journals such as Digestive and Liver Disease, Hepatology, Journal of Hepatology, Journal of Autoimmunity and Autoimmunity Reviews.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.